Thus, we underline that our study represents the first analysis of CDH17 immunohistochemical expression across the tumor core, tumor invasive front, tumor emboli, and lymph node metastasis in relation to clinicopathological features and survival outcomes, and its potential involvement as a prognostic factor in CRC. This evidence concerns the gene CDH17 and neoplasm.